The financial impact of the COVID-19 pandemic presents a potential risk to the future of clinical trials in rare diseases. Rare diseases by their nature are not very prevalent in the population, therefore, any treatment for a rare disease will only have a small number of beneficiaries. In addition, so-called orphan drug development takes around 18% […]
As COVID-19 continues to spread across the U.S., its impact on the U.S. health system is without precedent, with direct and indirect medical costs estimated to be in the hundreds of billions of dollars. On an individual basis, cost estimates from the Peterson Center on Healthcare and Kaiser Family Foundation (KFF) range from between $10,000 to […]
We have seen a digital revolution sweep across clinical practice, driven by the extraordinary circumstances of the coronavirus.
Many companies are facing challenging decisions on whether to proceed with clinical trials in the coming months as countries experience varying degrees of lockdown.
Telehealth, in particular, has been waiting for its moment. In the U.S., the first recorded instance of telemedicine happened more than 60 years ago (!) when the Nebraska Psychiatry Institute began using closed-circuit TV for psychiatric consultations.
Medical congresses – crucial for the presentation of trial data, scientific exchange and the opportunity to engage with medical professionals, patient advocates, media and analysts – have been cancelled, postponed or are moving to virtual/part virtual.